Amalgamated Bank Sells 2,371 Shares of Biogen Inc (BIIB)
Amalgamated Bank decreased its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 7.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 30,242 shares of the biotechnology company’s stock after selling 2,371 shares during the period. Amalgamated Bank’s holdings in Biogen were worth $10,685,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Honkamp Krueger Financial Services Inc. purchased a new stake in Biogen during the 3rd quarter worth $103,000. LeJeune Puetz Investment Counsel LLC purchased a new stake in Biogen during the 3rd quarter worth $107,000. NEXT Financial Group Inc purchased a new stake in Biogen during the 3rd quarter worth $133,000. Harvest Fund Management Co. Ltd increased its stake in Biogen by 122.0% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 384 shares of the biotechnology company’s stock worth $136,000 after buying an additional 211 shares during the period. Finally, Adviser Investments LLC increased its stake in Biogen by 745.7% during the 2nd quarter. Adviser Investments LLC now owns 389 shares of the biotechnology company’s stock worth $113,000 after buying an additional 343 shares during the period. Institutional investors and hedge funds own 87.16% of the company’s stock.
BIIB opened at $326.70 on Friday. The stock has a market capitalization of $65.02 billion, a PE ratio of 14.98, a P/E/G ratio of 1.25 and a beta of 0.95. Biogen Inc has a 1-year low of $249.17 and a 1-year high of $388.67. The company has a quick ratio of 2.46, a current ratio of 2.75 and a debt-to-equity ratio of 0.43.
In related news, EVP Michael D. Ehlers sold 1,000 shares of the business’s stock in a transaction dated Wednesday, September 26th. The shares were sold at an average price of $350.00, for a total transaction of $350,000.00. Following the completion of the sale, the executive vice president now owns 4,281 shares of the company’s stock, valued at approximately $1,498,350. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.29% of the stock is owned by corporate insiders.
Several equities research analysts recently issued reports on BIIB shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $400.00 price target on shares of Biogen in a research note on Monday, October 1st. Citigroup dropped their price target on shares of Biogen from $483.00 to $470.00 and set a “buy” rating on the stock in a research note on Monday, October 8th. Oppenheimer set a $400.00 price target on shares of Biogen and gave the stock a “buy” rating in a research note on Sunday, September 16th. Raymond James set a $400.00 price target on shares of Biogen and gave the stock a “buy” rating in a research note on Tuesday, October 23rd. Finally, BidaskClub raised shares of Biogen from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 7th. Nine research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $382.58.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.
Featured Story: Coverage Ratio
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.